High Net Worth Advisory Group’s Cytokinetics CYTK Stock Holding History

High Net Worth Advisory Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$330K	Hold	5,000	–	–	0.08%	184
2025 Q4	$318K	Hold	5,000	–	–	0.07%	182
2025 Q3	$275K	Buy	+5,000	New	+$206K	0.07%	197
2025 Q2	–	Sell	-5,000	Closed	-$201K	–	228
2025 Q1	$201K	Hold	5,000	–	–	0.06%	212
2024 Q4	$235K	Hold	5,000	–	–	0.07%	197
2024 Q3	$264K	Hold	5,000	–	–	0.07%	188
2024 Q2	$271K	Hold	5,000	–	–	0.08%	173
2024 Q1	$351K	Hold	5,000	–	–	0.11%	143
2023 Q4	$417K	Buy	+5,000	New	+$181K	0.16%	124
2023 Q1	–	Sell	-5,000	Closed	-$229K	–	273
2022 Q4	$229K	Hold	5,000	–	–	0.09%	171
2022 Q3	$242K	Hold	5,000	–	–	0.1%	161
2022 Q2	$196K	Hold	5,000	–	–	0.08%	186
2022 Q1	$184K	Hold	5,000	–	–	0.07%	193
2021 Q4	$228K	Buy	+5,000	New	+$193K	0.08%	178

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

High Net Worth Advisory Group's CYTK Position: Q1 2026 in Review

High Net Worth Advisory Group held its Cytokinetics (CYTK) position steady in Q1 2026 at 5,000 shares worth $330K. The position accounts for 0.08% of the portfolio, ranked #184.

High Net Worth Advisory Group first reported a position in CYTK in Q4 2021 and has held it in 14 quarters since. The position peaked at $417K in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

High Net Worth Advisory Group held 5,000 shares of Cytokinetics worth $330K as of Q1 2026.
High Net Worth Advisory Group left its Cytokinetics share count unchanged in Q1 2026.
Cytokinetics made up 0.08% of High Net Worth Advisory Group's portfolio in Q1 2026, its #184 holding.
High Net Worth Advisory Group first reported a position in Cytokinetics in Q4 2021 and has held it in 14 quarters since.
High Net Worth Advisory Group's Cytokinetics position peaked at $417K in Q4 2023.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on High Net Worth Advisory Group's 13F filing for Q1 2026, filed 17 Apr 2026.